vs
BIODESIX INC（BDSX）与CareDx, Inc.（CDNA）财务数据对比。点击上方公司名可切换其他公司
CareDx, Inc.的季度营收约是BIODESIX INC的3.8倍（$108.4M vs $28.8M）。CareDx, Inc.净利率更高（-3.8% vs -13.8%，领先10.1%）。BIODESIX INC同比增速更快（40.8% vs 25.2%）。过去两年BIODESIX INC的营收复合增速更高（39.3% vs 22.7%）
BIODESIX INC是一家专注于肿瘤与感染病领域的分子诊断企业，开发并商业化创新血液检测解决方案，主要服务北美地区的医疗机构、生物制药合作伙伴及患者，核心业务包括辅助临床决策的个性化医疗产品。
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
BDSX vs CDNA — 直观对比
营收规模更大
CDNA
是对方的3.8倍
$28.8M
营收增速更快
BDSX
高出15.6%
25.2%
净利率更高
CDNA
高出10.1%
-13.8%
两年增速更快
BDSX
近两年复合增速
22.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $28.8M | $108.4M |
| 净利润 | $-4.0M | $-4.1M |
| 毛利率 | — | — |
| 营业利润率 | -6.8% | -5.6% |
| 净利率 | -13.8% | -3.8% |
| 营收同比 | 40.8% | 25.2% |
| 净利润同比 | 51.8% | -104.7% |
| 每股收益（稀释后） | $-3.35 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDSXCDNA
| Q4 25 | $28.8M | $108.4M | ||
| Q3 25 | $21.8M | $100.1M | ||
| Q2 25 | $20.0M | $86.7M | ||
| Q1 25 | $18.0M | $84.7M | ||
| Q4 24 | $20.4M | $86.6M | ||
| Q3 24 | $18.2M | $82.9M | ||
| Q2 24 | $17.9M | $92.3M | ||
| Q1 24 | $14.8M | $72.0M |
净利润BDSXCDNA
| Q4 25 | $-4.0M | $-4.1M | ||
| Q3 25 | $-8.7M | $1.7M | ||
| Q2 25 | $-11.5M | $-8.6M | ||
| Q1 25 | $-11.1M | $-10.4M | ||
| Q4 24 | $-8.3M | $87.7M | ||
| Q3 24 | $-10.3M | $-10.6M | ||
| Q2 24 | $-10.8M | $-4.6M | ||
| Q1 24 | $-13.6M | $-19.9M |
营业利润率BDSXCDNA
| Q4 25 | -6.8% | -5.6% | ||
| Q3 25 | -32.4% | -0.2% | ||
| Q2 25 | -48.6% | -12.8% | ||
| Q1 25 | -50.9% | -15.8% | ||
| Q4 24 | -32.5% | 97.5% | ||
| Q3 24 | -47.3% | -16.6% | ||
| Q2 24 | -46.0% | -7.9% | ||
| Q1 24 | -74.4% | -31.3% |
净利率BDSXCDNA
| Q4 25 | -13.8% | -3.8% | ||
| Q3 25 | -40.0% | 1.7% | ||
| Q2 25 | -57.3% | -9.9% | ||
| Q1 25 | -61.8% | -12.2% | ||
| Q4 24 | -40.4% | 101.3% | ||
| Q3 24 | -56.5% | -12.8% | ||
| Q2 24 | -60.3% | -5.0% | ||
| Q1 24 | -91.9% | -27.6% |
每股收益（稀释后）BDSXCDNA
| Q4 25 | $-3.35 | $-0.08 | ||
| Q3 25 | $-1.16 | $0.03 | ||
| Q2 25 | $-0.08 | $-0.16 | ||
| Q1 25 | $-0.08 | $-0.19 | ||
| Q4 24 | $-5.02 | $1.60 | ||
| Q3 24 | $-1.40 | $-0.20 | ||
| Q2 24 | $-0.08 | $-0.09 | ||
| Q1 24 | $-0.14 | $-0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.0M | $177.2M |
| 总债务越低越好 | $50.0M | — |
| 股东权益账面价值 | $-2.5M | $303.1M |
| 总资产 | $87.5M | $413.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BDSXCDNA
| Q4 25 | $19.0M | $177.2M | ||
| Q3 25 | $16.6M | $194.2M | ||
| Q2 25 | $20.7M | $186.3M | ||
| Q1 25 | $17.6M | $230.9M | ||
| Q4 24 | $26.2M | $260.7M | ||
| Q3 24 | $31.4M | $240.9M | ||
| Q2 24 | $42.2M | $228.9M | ||
| Q1 24 | $11.5M | $215.9M |
总债务BDSXCDNA
| Q4 25 | $50.0M | — | ||
| Q3 25 | $50.0M | — | ||
| Q2 25 | $50.0M | — | ||
| Q1 25 | $40.0M | — | ||
| Q4 24 | $40.0M | — | ||
| Q3 24 | $40.0M | $0 | ||
| Q2 24 | $40.1M | $0 | ||
| Q1 24 | $40.1M | — |
股东权益BDSXCDNA
| Q4 25 | $-2.5M | $303.1M | ||
| Q3 25 | $-1.7M | $311.1M | ||
| Q2 25 | $1.1M | $327.4M | ||
| Q1 25 | $11.1M | $379.3M | ||
| Q4 24 | $20.9M | $378.4M | ||
| Q3 24 | $27.9M | $273.2M | ||
| Q2 24 | $36.3M | $264.7M | ||
| Q1 24 | $-5.5M | $256.2M |
总资产BDSXCDNA
| Q4 25 | $87.5M | $413.2M | ||
| Q3 25 | $88.7M | $432.3M | ||
| Q2 25 | $87.7M | $444.3M | ||
| Q1 25 | $86.2M | $489.6M | ||
| Q4 24 | $97.2M | $491.1M | ||
| Q3 24 | $102.7M | $477.0M | ||
| Q2 24 | $115.8M | $466.8M | ||
| Q1 24 | $87.2M | $452.4M |
负债/权益比BDSXCDNA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 43.95× | — | ||
| Q1 25 | 3.62× | — | ||
| Q4 24 | 1.92× | — | ||
| Q3 24 | 1.44× | 0.00× | ||
| Q2 24 | 1.10× | 0.00× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $778.0K | $21.4M |
| 自由现金流经营现金流 - 资本支出 | $692.0K | — |
| 自由现金流率自由现金流/营收 | 2.4% | — |
| 资本支出强度资本支出/营收 | 0.3% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-23.5M | — |
8季度趋势，按日历期对齐
经营现金流BDSXCDNA
| Q4 25 | $778.0K | $21.4M | ||
| Q3 25 | $-8.9M | $37.4M | ||
| Q2 25 | $-6.6M | $9.9M | ||
| Q1 25 | $-8.6M | $-26.6M | ||
| Q4 24 | $-4.1M | $21.9M | ||
| Q3 24 | $-10.7M | $12.5M | ||
| Q2 24 | $-18.6M | $18.9M | ||
| Q1 24 | $-15.3M | $-15.3M |
自由现金流BDSXCDNA
| Q4 25 | $692.0K | — | ||
| Q3 25 | $-8.9M | — | ||
| Q2 25 | $-6.6M | — | ||
| Q1 25 | $-8.7M | — | ||
| Q4 24 | $-4.9M | — | ||
| Q3 24 | $-10.9M | — | ||
| Q2 24 | $-20.5M | — | ||
| Q1 24 | $-15.5M | — |
自由现金流率BDSXCDNA
| Q4 25 | 2.4% | — | ||
| Q3 25 | -41.0% | — | ||
| Q2 25 | -33.1% | — | ||
| Q1 25 | -48.3% | — | ||
| Q4 24 | -24.2% | — | ||
| Q3 24 | -60.1% | — | ||
| Q2 24 | -114.3% | — | ||
| Q1 24 | -104.9% | — |
资本支出强度BDSXCDNA
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | 10.7% | — | ||
| Q1 24 | 1.6% | — |
现金转化率BDSXCDNA
| Q4 25 | — | — | ||
| Q3 25 | — | 22.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDSX
| Diagnostic Tests | $25.1M | 87% |
| Development Services | $3.6M | 13% |
CDNA
| Services | $78.4M | 72% |
| Patient And Digital Solutions | $16.8M | 15% |
| Products | $13.3M | 12% |
